AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
Orthocell (ASX:OCC) secures distributor coverage across multiple US states for Remplir
Pre-launch groundwork includes medical education and hospital engagement strategies
Company preparing for further regulatory steps in Europe and the UK
Orthocell Ltd (ASX:OCC), a health sector constituent with ties to the asx 200, is advancing its regenerative medicine strategy with the expansion of its US distribution footprint for Remplir, a collagen-based product used in peripheral nerve procedures. The company has now established commercial agreements with a growing number of specialist distributors, surpassing its early-stage rollout benchmarks and covering a wide regional area across the United States.
The US distribution network spans various states and forms a key component of Orthocell’s broader entry into the world’s largest healthcare market. This follows the clearance for Remplir from the US Food and Drug Administration, achieved through the 501(k) pathway. The company is focused on securing early sales traction while embedding long-term infrastructure for product delivery.
Specialist distributor network supports early-stage growth
Orthocell’s distributor agreements involve professionals experienced in nerve repair who operate established channels within surgical practices and hospital systems. These partners work under a commission-based model to drive product engagement and support medical practitioners.
The network’s activities are being reinforced through sales initiatives, targeted educational outreach, and engagement with plastic and orthopaedic surgeons. Distributor training and preparation have been led by Orthocell’s in-house teams, focusing on ensuring that clinical professionals are adequately equipped to work with the product.
Key hospitals across the US are being engaged to formalise supplier relationships. In addition, Orthocell has been building a panel of clinical experts to support broader awareness through events and roadshows aimed at showcasing the benefits of Remplir.
Hybrid strategy enables structured market entry
The company is implementing a hybrid commercial strategy by blending its own management oversight with local sales expertise. Internal directors, supported by territory-based managers, oversee the distributor portfolio to maintain consistency in messaging and sales quality.
This structure allows Orthocell to maintain direct visibility over its US operations while also leveraging the agility and local knowledge of independent distribution networks. Activities are coordinated to align with a centralised launch plan, with specific attention given to early-stage execution.
The product rollout also aligns with a broader commercial roadmap focused on advancing Orthocell’s global expansion. Remplir is already approved for use in Australia, New Zealand, Thailand, and Canada, forming part of a wider regenerative suite that includes Striate for dental procedures, SmrtGraft for tendon applications, and autologous therapies for musculoskeletal injury treatment.
Strategic planning for international regulatory milestones
With internal resources dedicated to US market momentum, the company is also progressing toward regulatory filings in both the United Kingdom and the European Union. Submission efforts are underway, supporting the firm’s intention to extend market reach across additional healthcare systems.
Orthocell’s financial position remains stable, enabling its product development and commercial initiatives. Its expansion plans are being managed in alignment with its clinical, sales, and medical affairs frameworks to facilitate controlled and efficient growth in global markets.
As a part of its broader industry positioning, the company is navigating an addressable market in nerve repair that spans numerous regions and includes a significant number of procedures annually. Orthocell continues to refine its operational strategy as it moves into post-clearance execution phases across key global jurisdictions.
